BioNTech Shares Fall After BMO Downgrade and Price Target Cut
BioNTech SE (BNTX) shares dropped 1.2% to $102.55 in premarket trading after BMO Capital downgraded the stock to Market Perform and cut its price target to $105 from $128, citing lower COVID vaccine demand and inventory drawdowns. The company also terminated a Phase 2 colorectal cancer trial and reduced its 2026 revenue guidance to €1.6-1.9 billion from €2.0-2.3 billion.
How this was made
The 30-second read
Why it matters
The downgrade and guidance cut could trigger short covering and increased volatility.
Market read
Primary catalyst for BNTX price movement; sector peers may be indirectly affected.
What to watch
Potential upside from new partnership deals or cost reductions not yet disclosed.
Background
BioNTech is a leading mRNA vaccine developer; recent COVID vaccine demand has softened.
Ticker impact
BMO downgraded BioNTech to Market Perform, cut price target to $105 and the company cut its 2026 revenue guidance.
Potential further decline toward $100-$105 range in the short term.
Analyst downgrade combined with lower revenue outlook and trial termination creates a clear bearish catalyst.
Market effects
Biotech sector may see modest pressure as a major mRNA player faces demand headwinds.
European markets could react to reduced COVID vaccine demand signals.
Limited to BioNTech and its peers; no broad macro effect.
Counterpoint
The price cut may be overblown if oncology pipeline delivers later breakthroughs.
Key entities
- AnalystBMO Capital
Downgraded BioNTech and cut price target.
- PartnerRoche/Genentech
Terminated colorectal cancer trial with BioNTech.
